This website uses cookies

Cookies are required to understand how you and other visitors use our websites and applications and to improve your browsing experience.
By using this website without changing your browser settings, you consent to the use of cookies and other device identifiers.

Bausch Health is proud to introduce Emerade HEALTHCARE
PROFESSIONALS

AN EPINEPHRINE AUTO-INJECTOR FOR THE EMERGENCY TREATMENT OF ANAPHYLAXIS

EMERADE HAS A 0.5 MG DOSE OPTION FOR PATIENTS EXCEEDING 60 KG.1,2*

For patients exceeding 60 kg, the recommended dose is 0.3 to 0.5 mg depending on clinical judgement.

DESIGNED FOR IM INJECTION1

  • When administered subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action.

SIMPLE & EASY-TO-USE DESIGN1

  • Contains an obvious opening at the needle end, and none at the opposite end.
  • Designed to minimize the risk of unintentional injection. Emerade should be used for intramuscular injection only on the outer thigh.

* Comparative significance is unknown.
See Product Monograph for complete dosing and administration instructions.

Emerade is indicated for the emergency treatment of anaphylactic reactions in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Select dose according to patient’s body weight and age.

  • FREQUENTLY ASKED QUESTIONS1

    • In children:

      • Between 15-30 kg body weight: Usual dose is 0.15 mg (not available in Canada)
      • >30 kg body weight: Usual dose is 0.3 mg

      In adults:

      • <60 kg body weight: Recommended dose is 0.3 mg
      • >60 kg body weight: Recommended dose is 0.3 to 0.5 mg depending on clinical judgement

      • The dosage recommendations for adult patients should be followed for adolescent patients >30 kg body weight.
      • Emerade 0.5 mg is not recommended for use in children.
    • healthcare-professionals.faq.questions.2.answer.img-alt

      For adult patients exceeding 60 kg body weight, the recommended dose is 0.3 to 0.5 mg depending on clinical judgement. For adult patients under 60 kg, the recommended dose is 0.3 mg. For a child that weighs over 30 kg, the recommended dose is 0.3 mg.

    • The syringe in Emerade has a 25 mm needle. The needle protrudes 23 mm for intramuscular injection in the 0.3 mg and 0.5 mg pen. The needle length enables injection through clothing.

    • Emerade has a durable, plastic outer case to protect the auto-injector and labelling.
      It is also labelled with different colours to distinguish the different dosages.

      Emerade is available in a pack size of one pre-filled pen.

    • You can always sign up to receive a free trainer device so that you can show your patients.
      You can also instruct your patients or caregivers to watch the online video to learn more.

      You can also refer to the Instructions for use section in the Product Monograph for complete administration information.

    • Emerade can be purchased with or without a prescription.

    • It is recommended that patients carry 2 epinephrine auto-injectors, like Emerade, at all times.

      The first dose should be administered as soon as symptoms of anaphylaxis are recognized.
      If there is no resolution of anaphylaxis, a second injection with an additional Emerade may be administered 5 – 15 minutes after the first injection.

    • Refer to the video to see how patients or caregivers can administer their Emerade.

      You can also refer to the Instructions for use section in the Product Monograph for complete administration information.

    • When the injection is completed, the plunger is visible in the inspection window by lifting the label. Some liquid may remain in the auto-injector after the injection. The auto-injector cannot be re-used.

    • To use Emerade, gently press it against the outer side of the thigh. A click can be heard when the injection goes into the muscle.

    • During injection, Emerade is held against the thigh for about 5 seconds.

    • Store at room temperature (15°C to 25°C), do not freeze and keep it out of reach and sight of children.

      • If the solution is discoloured or contains particles. (The solution can be examined by lifting the label.)
      • If Emerade has expired. (The expiry date is indicated on the label.)

Indications and clinical use:

Emerade is indicated for the emergency treatment of anaphylactic reactions in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Select dose according to patient’s body weight and age.

Emerade is intended for immediate self-administration for emergency treatment of severe allergic reactions (Type I), including anaphylaxis associated with e.g. peanuts, tree nuts, shellfish, fish, milk, eggs, wheat, stinging insects, and medications.

Emerade is designed as emergency supportive therapy only and not as a replacement or substitute for subsequent medical care.

MOST SERIOUS WARNING AND PRECAUTION

Emergency treatment: In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care.

Following treatment of anaphylaxis, the patient must stay within close proximity to a hospital or where he or she can call 911 for the next 48 hours.

CONTRAINDICATIONS

No absolute contraindications to the use of epinephrine in a life-threatening allergic situation.

RELEVANT WARNINGS AND PRECAUTIONS

  • Emergency treatment only
  • More than two sequential doses of epinephrine should only be administered under direct medical supervision
  • Avoid use in patients with cardiogenic, traumatic, or hemorrhagic shock; cardiac dilation; and/or cerebral arteriosclerosis
  • Use with caution in patients with cardiac arrhythmias, coronary artery or organic heart disease, hypertension, hyperthyroidism or in patients who are on medications that may sensitize the heart to arrhythmias
  • Patients with organic brain damage or Parkinson’s disease
  • Patients with narrow-angle glaucoma
  • Patients with sulfite sensitivity
  • Patients with concomitant asthma
  • Risk of biphasic anaphylaxis
  • Diabetes
  • Patients with a thick subcutaneous fat layer
  • Pregnant and nursing patients
  • Do not inject into buttock, digits, hands or feet
  • Geriatric patients
  • Serious injection site infections

FOR MORE INFORMATION

Please consult the Product Monograph at: pdf.hres.ca/dpd_pm/00055405.PDF for important information relating to adverse reactions, drug interactions and dosing information which has not been discussed in this piece. The Prescribing Information is also available by calling us at: 1-800-361-4261.

REFERENCES

  1. Emerade Product Monograph. Bausch Health Canada Inc. June 15, 2020.
  2. Data on File